PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 1,739 Shares of Stock

PTC Therapeutics, Inc. (NASDAQ:PTCT) VP Mark Elliott Boulding sold 1,739 shares of PTC Therapeutics stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $76.95, for a total transaction of $133,816.05. Following the completion of the transaction, the vice president directly owned 119,162 shares in the company, valued at approximately $9,169,515.90. The trade was a 1.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Mark Elliott Boulding also recently made the following trade(s):

• On Wednesday, January 7th, Mark Elliott Boulding sold 4,879 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.44, for a total transaction of $377,829.76.
• On Monday, January 5th, Mark Elliott Boulding sold 2,266 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.55, for a total transaction of $171,196.30.
• On Monday, November 17th, Mark Elliott Boulding sold 2,812 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.99, for a total value of $213,683.88.

PTC Therapeutics Price Performance

Shares of PTCT stock opened at $76.85 on Friday. PTC Therapeutics, Inc. has a 1-year low of $35.95 and a 1-year high of $87.50. The stock’s fifty day moving average price is $76.43 and its 200 day moving average price is $62.53. The company has a market cap of $6.17 billion, a price-to-earnings ratio of 8.98 and a beta of 0.49.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of ($1.19) by $1.39. The company had revenue of $211.01 million during the quarter, compared to analysts’ expectations of $177.42 million. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The firm’s revenue was up 7.2% compared to the same quarter last year. During the same period last year, the business posted ($1.39) earnings per share. As a group, equities research analysts anticipate that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Key Stories Impacting PTC Therapeutics

Here are the key news stories impacting PTC Therapeutics this week:

• Neutral Sentiment: Analysts maintain a consensus rating of “Hold” on PTCT, signaling muted broker enthusiasm and limited near-term upward catalyst from Wall Street. Article Title
• Neutral Sentiment: PTC reported an inducement grant of 300 restricted stock units for a new non-executive hire under Nasdaq Rule 5635(c)(4); a routine, small hire award with minimal direct financial impact but modest dilution. Article Title
• Negative Sentiment: A company director executed a sizable sale valued at $916,200, a notable insider disposition that can weigh on investor sentiment even if done for personal reasons. Article Title
• Negative Sentiment: Broad insider selling disclosed in SEC Form 4 filings: multiple senior executives (including CEO Matthew B. Klein, CFO Pierre Gravier, EVP Lee Golden, VP Mark Boulding, CAO Christine Utter and others) sold shares in early January. These trades—ranging from small lots to multi-thousand-share sales—represent notable reductions in insider positions and may signal profit-taking or diversification, which can pressure the stock until a clear operational/strategy signal offsets them. Representative filings: SEC Form 4

Hedge Funds Weigh In On PTC Therapeutics

A number of institutional investors have recently modified their holdings of PTCT. Smartleaf Asset Management LLC lifted its holdings in shares of PTC Therapeutics by 101.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 236 shares during the period. Optiver Holding B.V. lifted its holdings in PTC Therapeutics by 96.5% in the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 249 shares during the period. Comerica Bank boosted its position in PTC Therapeutics by 868.5% in the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 469 shares in the last quarter. IFP Advisors Inc grew its stake in shares of PTC Therapeutics by 68.1% during the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 310 shares during the period. Finally, PNC Financial Services Group Inc. increased its holdings in shares of PTC Therapeutics by 42.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 295 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages have issued reports on PTCT. Cowen restated a “hold” rating on shares of PTC Therapeutics in a research note on Wednesday, November 5th. TD Cowen upped their target price on PTC Therapeutics from $50.00 to $63.00 and gave the company a “hold” rating in a research report on Wednesday, November 5th. Morgan Stanley reaffirmed an “overweight” rating and set a $90.00 price target on shares of PTC Therapeutics in a research report on Thursday. Citigroup increased their price objective on PTC Therapeutics from $50.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Finally, Wall Street Zen upgraded PTC Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, January 3rd. Nine equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, PTC Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $77.27.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.